Each year, roughly 300,000 women worldwide receive an ovarian cancer diagnosis that carries a five-year survival rate of only 40 percent — a disease where meaningful progress has been rare for nearly three decades. In August 2026, a small biotech called Imunon presented data suggesting that a DNA-based immunotherapy, delivered directly into tumors, may be quietly bending that curve. The numbers from their Phase 2 trial — nearly fifteen additional months of median survival, and more than two years gained for those who continued into maintenance therapy — are not yet the final word, but they rep
Imunon's IMNN-001 Shows 45-Month Survival in Ovarian Cancer Phase 2 Trial
Approximately 300,000 women diagnosed annually with ovarian cancer; current five-year survival rate is approximately 40%, indicating significant unmet medical need.